Prolia (Denosumab) Cost in Ohio 2026

What Does Prolia (Denosumab) Cost Without Insurance in Ohio?

The Amgen wholesale acquisition cost for Prolia in 2026 sits at approximately $1,500 per 60 mg prefilled syringe. Because each injection is given only every six months, the annual list-price burden is around $3,000, but almost no Ohio patient actually pays that figure out of pocket. Most retail pharmacies across the state price the drug within a few dollars of the Amgen wholesale acquisition cost, so shopping between CVS, Rite Aid, and independent pharmacies typically saves less than $50 per dose.

Cash-pay patients who do not qualify for any assistance program face the full $1,500 charge. GoodRx and similar discount aggregators show Ohio pharmacy prices in the $1,380 to $1,510 range depending on ZIP code and specific chain. Prices in Columbus and Cleveland tend to run marginally higher than rural Ohio pharmacies because of local dispensing-fee structures, though the difference is rarely more than $40. Prolia is FDA-approved as a prescription-only biologic, which means it cannot be purchased over the counter or through veterinary channels.

The cost picture changes significantly once insurance, manufacturer coupons, or assistance programs enter the equation. Those pathways are covered in detail in the sections below.

How Ohio Medicaid Handles Prolia Coverage

Ohio Medicaid does not cover Prolia (denosumab) for the osteoporosis indication in 2026. Ohio Department of Medicaid formulary data show that denosumab coverage under the Medicaid drug benefit is restricted to type 2 diabetes-related bone-disease coding in specific managed care contracts, not for postmenopausal or glucocorticoid-induced osteoporosis.

That gap matters for the roughly 3.3 million Ohioans enrolled in Medicaid. Patients whose only payer is Ohio Medicaid and who need denosumab for osteoporosis must either seek a prior authorization appeal, transition to a covered alternative such as alendronate (available for under $10 per month generic), or explore the Amgen patient assistance program described later. Some Ohio Medicaid managed care organizations (MCOs) maintain their own drug lists that occasionally differ from the state fee-for-service list, so a specific MCO formulary lookup is worth the 10-minute call to member services.

Prior authorization appeals citing the FREEDOM trial data and the Endocrine Society Clinical Practice Guideline on osteoporosis occasionally succeed when a prescriber documents failure of or contraindication to bisphosphonates.

Medicare Coverage for Prolia in Ohio

Medicare Part B, not Part D, covers Prolia for most Ohio patients because the drug is typically administered in a physician's office or infusion center. Under Part B, denosumab qualifies as an incident-to injectable drug. After meeting the annual Part B deductible ($257 in 2025, with 2026 figures pending CMS finalization), standard Medicare pays 80% of the Medicare-approved amount and the patient owes 20% coinsurance.

For Ohio Medicare beneficiaries with a Medigap (supplemental) policy, that 20% coinsurance may be fully or partially covered depending on the plan letter. Plan G, the most popular new Medigap plan sold in Ohio, covers the 20% coinsurance entirely after the patient meets the Part B deductible, bringing the effective out-of-pocket cost per injection to near zero. Medicare Advantage plans sold by Anthem, Humana, and Medical Mutual of Ohio typically follow Medicare's coverage rules for Part B drugs but may require a step-through authorization showing prior bisphosphonate use or documented intolerance.

CMS data on Medicare Part B drug coverage confirm that denosumab carries a J-code (J0897) used for billing physician-administered injections, which is a key administrative detail Ohio patients can reference when contacting their insurer.

Commercial Insurance and Prior Authorization in Ohio

Major Ohio commercial insurers, including Anthem Blue Cross Blue Shield of Ohio, Medical Mutual, SummaCare, and AultCare, generally cover Prolia under their medical benefit for FDA-approved osteoporosis indications. Most require a prior authorization. Typical criteria include:

• A documented bone mineral density T-score of -2.5 or below (osteoporosis), or a T-score between -1.0 and -2.5 (osteopenia) with a FRAX 10-year major fracture probability of 20% or higher
• Documented trial of or contraindication to an oral bisphosphonate
• Prescriber documentation of adequate calcium and vitamin D supplementation

The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines state that denosumab is an appropriate first-line choice for patients at very high fracture risk, which can strengthen a prior authorization appeal when bisphosphonate use is contraindicated due to renal impairment (eGFR <35 mL/min/1.73m²).

Once approved under the medical benefit, most commercial plans assign a specialist office-visit co-pay to the injection visit rather than a separate drug co-pay, which can hold the cost to $40 to $75 per visit.

The Amgen Prolia Savings Card: How It Works in Ohio

Amgen operates a co-pay assistance program for Prolia that can reduce out-of-pocket costs to $0 per dose for eligible commercially insured patients. Enrollment is online at the Amgen Assist 360 portal. Key eligibility criteria include:

• Must have commercial insurance (not Medicare, Medicaid, CHIP, or any federal health program)
• Annual household income below a set threshold (Amgen adjusts this periodically)
• Valid prescription from a licensed Ohio prescriber

Once enrolled, the card is used at the prescribing physician's office or pharmacy. Amgen pays the co-pay or coinsurance balance up to a calendar-year maximum that has historically been set at $3,600. Because Prolia is only two injections per year, the calendar-year cap is rarely reached.

Ohio patients should verify enrollment annually, as the program resets each January 1. A small number of Ohio independent pharmacies have reported administrative delays in processing the card on the first fill; calling the Amgen Assist 360 hotline at least one week before the scheduled injection appointment resolves most issues.

Patient Assistance Program for Uninsured or Underinsured Ohioans

For Ohio patients with no insurance or who do not qualify for the co-pay card, Amgen's patient assistance program (Prolia FIRST STEP) provides free medication to qualifying patients. Income limits are tied to federal poverty level guidelines published annually by HHS. In prior years the cutoff has been 500% of the federal poverty level, meaning a single Ohio adult earning under roughly $75,000 annually could qualify.

Applications require physician certification, proof of income, and confirmation of no third-party insurance coverage. Processing typically takes three to four weeks. Ohio-based patient advocates at the Ohio State University Wexner Medical Center and Cleveland Clinic have documented high approval rates when applications are submitted with complete documentation on the first attempt.

Is Compounded Denosumab Legal in Ohio?

Compounded denosumab is legally available through licensed 503A compounding pharmacies in Ohio. FDA regulations for 503A pharmacies allow compounding of drugs not on the FDA's Difficult to Compound list for individual patients with a valid prescription, and denosumab is not currently on that list.

Several Ohio-based and out-of-state 503A pharmacies licensed to ship into Ohio offer compounded denosumab at dramatically lower prices than brand Prolia. Reported pricing in early 2026 ranges from no upfront cost under certain telehealth subscription models to roughly $150 to $350 per dose depending on the pharmacy and concentration.

There are genuine clinical caveats. Brand Prolia uses a proprietary formulation with demonstrated bioequivalence data supporting its 68% vertebral fracture reduction shown in the FREEDOM trial. Compounded versions lack that regulatory-reviewed bioequivalence package. The FREEDOM trial (N=7,868) published in the New England Journal of Medicine showed that denosumab 60 mg every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared with placebo. Those efficacy figures are tied to the branded molecule as tested. Whether a specific compounded formulation replicates that pharmacokinetic profile depends on the individual pharmacy's quality processes.

Ohio patients choosing a compounded route should confirm the pharmacy holds active Ohio Board of Pharmacy licensure and, ideally, a USP 797 sterile compounding certification.

Telehealth Prescribing of Prolia in Ohio: What to Know

Ohio permits telehealth prescribing of Prolia. Ohio Revised Code and the Ohio Medical Board's telehealth rules, updated following the COVID-19 public health emergency, allow physicians and advanced practice providers to establish a valid patient-provider relationship via synchronous audio-video visit and then prescribe controlled and non-controlled medications including biologics.

Practically, this means an Ohio patient can obtain a Prolia prescription through a licensed telehealth platform without an initial in-person visit, provided the provider:

1. Reviews relevant bone mineral density data (DXA scan results)
2. Documents the clinical indication and fracture risk assessment
3. Performs a synchronous video visit that meets Ohio's telehealth standards

The injection itself still requires a clinical setting because Prolia is a subcutaneous injection that most patients receive in a physician's office, rheumatology clinic, or infusion suite. Some Ohio home health agencies can administer the injection at the patient's residence under a physician order, which broadens access for patients with mobility limitations.

HealthRX telehealth providers licensed in Ohio can initiate the prescribing process, coordinate the DXA review, and send the prescription directly to a preferred Ohio pharmacy or the patient's in-office injection site.

Comparing Ohio's Cost Options Side by Side

Understanding the full range of options helps Ohio patients and their prescribers choose the most cost-effective path. The table below summarizes the major scenarios.

| Access Route | Approximate Ohio Cost Per Injection | Notes | |---|---|---| | Uninsured, cash pay | ~$1,500 | List price; minimal variation across chains | | Amgen co-pay card (commercial insurance) | $0 | Subject to program eligibility and annual maximum | | Medicare Part B with Medigap Plan G | ~$0 after deductible | 20% coinsurance covered by plan | | Medicare Part B without Medigap | ~$300 per injection | 20% of Medicare-approved amount | | Ohio Medicaid (osteoporosis) | Not covered | PA appeal may succeed in limited cases | | Compounded denosumab via 503A | $0 to $350 | Varies by pharmacy; not FDA-reviewed for equivalence | | Amgen FIRST STEP assistance program | $0 | Requires income qualification; 3-4 week processing |

Clinical Context: Why Denosumab Costs What It Does

Denosumab is a fully human monoclonal antibody targeting RANK ligand (RANKL), a protein that drives osteoclast activity. Inhibiting RANKL suppresses bone resorption more completely than bisphosphonates in head-to-head comparisons. The FREEDOM trial enrolled 7,868 postmenopausal women aged 60 to 90 with a lumbar spine or total hip T-score between -2.5 and -4.0. At 36 months, the denosumab group showed a 68% relative risk reduction for new vertebral fractures (P<0.001) versus placebo.

That biologic manufacturing process, which involves mammalian cell culture, purification, and fill-finish under aseptic conditions, drives a cost structure that generic manufacturers cannot replicate with standard chemistry. Amgen holds the branded Prolia patent through at least 2025, with patent litigation ongoing regarding potential biosimilar entry. No FDA-approved denosumab biosimilar was available for routine Ohio pharmacy dispensing as of early 2026.

The FDA's approved labeling for Prolia covers six indications including postmenopausal osteoporosis, bone loss in men with osteoporosis, glucocorticoid-induced osteoporosis, and bone loss associated with certain cancer treatments. The manufacturing and regulatory overhead across all those indications is reflected in the list price.

Discontinuation Risk: The Rebound Effect Ohio Patients Must Know

Stopping denosumab without transitioning to a bisphosphonate carries a documented risk of rapid bone mineral density loss and rebound vertebral fractures. A 2017 case series published in Osteoporosis International described multiple vertebral fractures occurring within 18 months of Prolia discontinuation in patients who did not receive bridging antiresorptive therapy.

Ohio patients who cannot afford the next dose for any reason, including a coverage lapse, should contact their prescriber before missing the 6-month injection window. Oral bisphosphonates (alendronate 70 mg weekly is available in Ohio for under $10/month as a generic) are the standard bridging strategy recommended by the Endocrine Society.

Missing a dose is not a minor inconvenience with Prolia. It carries measurable clinical risk. That safety consideration is one reason cost navigation for this drug deserves careful attention.

What Ohio Patients Should Do Before Their Next Injection

A practical pre-injection checklist for Ohio Prolia patients:

1. Confirm insurance coverage and prior authorization renewal (many PAs expire annually)
2. Verify Amgen savings card enrollment at Amgen Assist 360 if using commercial insurance
3. If uninsured, submit FIRST STEP application at least 4 weeks before the injection due date
4. If considering a 503A compounded version, verify Ohio Board of Pharmacy licensure of the compounding pharmacy
5. Confirm calcium (1,000 to 1 to 200 mg/day) and vitamin D (at least 400 IU/day) supplementation is ongoing, per FDA label requirements
6. Schedule a DXA scan every 1 to 2 years to document response, per National Osteoporosis Foundation guidelines